title: Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: implications for tipranavir use.
authors.affiliation: Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
authors.forename: Oscar
authors.initials: O
authors.lastname: Gallego
authors.forename: Carmen
authors.initials: C
authors.lastname: de Mendoza
authors.forename: Angélica
authors.initials: A
authors.lastname: Corral
authors.forename: Ana
authors.initials: A
authors.lastname: Barrios
authors.forename: Vincent
authors.initials: V
authors.lastname: Soriano
mesh_terms: D024921:Drug Resistance, Multiple, Viral / Q000235:genetics*; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D009154:Mutation; D011725:Pyridines / Q000494:pharmacology*; D011753:Pyrones / Q000494:pharmacology*; D019438:Ritonavir / Q000494:pharmacology*; D013449:Sulfonamides
chemical_list: D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; D019438:Ritonavir; C107201:tipranavir